343 related articles for article (PubMed ID: 34413006)
1. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
[TBL] [Abstract][Full Text] [Related]
3. An EUA for baricitinib (Olumiant) for COVID-19.
Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
[No Abstract] [Full Text] [Related]
4. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
[TBL] [Abstract][Full Text] [Related]
6. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
[TBL] [Abstract][Full Text] [Related]
7. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.
Frishman WH
Cardiol Rev; 2021 May-Jun 01; 29(3):109. PubMed ID: 33758124
[No Abstract] [Full Text] [Related]
8. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
[TBL] [Abstract][Full Text] [Related]
9. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
Quek E; Tahir H; Kumar P; Hastings R; Jha R
Br J Hosp Med (Lond); 2021 Mar; 82(3):1-9. PubMed ID: 33792391
[TBL] [Abstract][Full Text] [Related]
10. Compassionate Use of Remdesivir in Children With Severe COVID-19.
Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
Troyer BS; Kovacic Scherrer N; Garavaglia J
J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
[No Abstract] [Full Text] [Related]
14. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
[TBL] [Abstract][Full Text] [Related]
15. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
Congly SE; Varughese RA; Brown CE; Clement FM; Saxinger L
Sci Rep; 2021 Sep; 11(1):17787. PubMed ID: 34493774
[TBL] [Abstract][Full Text] [Related]
16. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
17. A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone.
Jo YH; Hwang Y; Choi SH
J Korean Med Sci; 2021 Jul; 36(29):e203. PubMed ID: 34313036
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment.
Chang MC; Wu PF; Ho YC; Lin WY; Wu CY; Liu SY; Liu CJ; Lin YT
J Infect Public Health; 2024 Jul; 17(7):102460. PubMed ID: 38820894
[TBL] [Abstract][Full Text] [Related]
19. Real-life use of remdesivir in hospitalized patients with COVID-19.
Garcia-Vidal C; Meira F; Cózar-Llistó A; Dueñas G; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Cardozo C; Hernandez-Meneses M; Alonso-Navarro R; Rico V; Agüero D; Bodro M; Morata L; Jordan C; Lopera C; Ambrosioni J; Segui F; Grafia N; Castro P; García F; Mensa J; Martínez JA; Sanjuan G; Soriano A;
Rev Esp Quimioter; 2021 Apr; 34(2):136-140. PubMed ID: 33675220
[TBL] [Abstract][Full Text] [Related]
20. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
